17 research outputs found

    The Effect of Household Food Processing on Pesticide Residues in Oranges (<i>Citrus sinensis</i>)

    No full text
    In this study, the effect of various household food-processing methods (washing, peeling, processing into jam and fruit juice, freezing, storage) on pesticide residues (abamectin, buprofezin, ethoxazole, imazalil, and thiophanate-methyl) in oranges was investigated. Residue analyses were performed by quick-easy-cheap-efficient-rugged-safe (QuEChERS) extraction and liquid chromatography coupled with triple quadrupole mass spectrometry (LC-MS/MS) analysis. The limit of quantification of the method for each pesticide was 10 µg/kg. Physicochemical properties of the pesticides and the type of the food process had a considerable effect on the fate of pesticide residue. Pesticide residues were mostly dispersed on orange peels and washing with tap water decreased the residue levels by 26–84%. The amount of residue in oranges was reduced by 63–100% during fruit juice processing, while residues were removed by 90–100% after jam processing. Pesticides with a high octanol–water coefficient were absorbed by the wax of the orange peel, therefore they remained on the peel and could not easily be removed by washing. Moreover, pesticides with lower water solubility did not diffuse easily through the fruit juices from the pulp section of the fruit. The processing factor was greater than 1 for the separation of the orange peel and less than 1 for the washing step and jam and fruit juice productions

    The evaluation of headache in patients with schizophrenia: A case-control study

    No full text
    The evaluation of headache in patients with schizophrenia: a case-control study Objective: The aim of this study is to explore the frequency and the types of headache in patients with schizophrenia and to compare it with the healthy control group. Method: A hundred and one patients and eighty nine healthy subjects were included in this case-control study. Socio-demographic data form, structured clinical interview for DSM disorders type 1 (SCID-1), Scale for the Assessment of the Negative Symptoms (SANS) and of the Positive Symptoms (SAPS) were applied. The subjects with headache were consulted to the neurology clinic. Results: The prevalence of headache in the patient group was 38.6% whereas the prevalence of headache in the control group was 37.1%. Tension type headache (TTH) was the most prominent type in both group (31.7% of patients, 18.0% of controls) and the presence of TTH in patients with schizophrenia was found statistically significant. Migraine type headache was detected in 2.0% of patients and 11.2% of controls. The ratio of headache was lesser in patients than in the controls. Conclusion: Schizophrenic patients have headache as much as the healthy subjects but they complain less about their headache than the controls do. Further studies with larger samples in patients with schizophrenia would present the importance of the issue and improve the quality of life in patients with schizophrenia contributing the analgesia

    The Evaluation of Headache in Patients with Schizophrenia: A Case- Control Study

    No full text
    Amaç: Bu çalışmada şizofrenli hastalarda sağlıklı kontrol grubu ile karşılaştırarak baş ağrısı sıklığı ve hangi tip baş ağrılarının olduğunun araştırılması amaçlandı.Yöntem: Çalışmaya 101 hasta ve 89 sağlıklı kontrol grubu alındı. Hastalara araştırmacılar tarafından hazırlanan, hastanın sosyo-demografik özelliklerinin, hastalığı ile ilgili bilgilerin ve baş ağrısı ile ilgili soruların yer aldığı sosyodemografik veri formu, DSM-IV eksen 1 tanı ölçütlerine göre hazırlanmış yapılandırılmış bir klinik görüşme formu olan SCID-1 ve Pozitif ve Negatif Belirtileri Değerlendirme Ölçeği uygulandı. Şu anda ya da geçmişte baş ağrısı olduğunu ifade eden hastalar baş ağrısının değerlendirilmesi amacıyla nöroloji polikliniğine yönlendirildi. Bulgular: Şizofrenli hasta grubunun %38.6'sı baş ağrısı tanımlarken, kontrol grubunda bu oran %37.1 olarak bulundu. Her iki grupta da en fazla gerilim tipi baş ağrısı (GTBA) görülmesine rağmen (hasta grubu=%31.7, kontrol grubu=%18) şizofreni grubunda GTBA kontrol grubundan anlamlı olarak daha fazla bulundu. Migren tipi baş ağrısı ise kontrol grubunun %11.2'sinde görülürken, hasta grubunun %2'sinde görülmekteydi. Şizofrenili hasta grubu kontrol grubuna göre baş ağrısı yakınmasını daha az dile getirmekteydi.Sonuç: Bu çalışmada şizofrenili hastaların normal popülasyon kadar baş ağrısına maruz kaldığı, baş ağrısı yakınmasını normal topluma göre daha az dile getirdikleri sonucu elde edilmiştir. Bu konuda yapılacak geniş örneklemli çalışmalar ve oluşturulacak tedavi protokolleri şizofrenili hastaların yaşam kalitesinin artmasına da katkı sağlayabilirObjective: The aim of this study is to explore the frequency and the types of headache in patients with schizophrenia and to compare it with the healthy control group. Method: A hundred and one patients and eighty nine healthy subjects were included in this case-control study. Socio-demographic data form, structured clinical interview for DSM disorders type 1 (SCID-1), Scale for the Assessment of the Negative Symptoms (SANS) and of the Positive Symptoms (SAPS) were applied. The subjects with headache were consulted to the neurology clinic. Results: The prevalence of headache in the patient group was 38.6% whereas the prevalence of headache in the control group was 37.1%. Tension type headache (TTH) was the most prominent type in both group (31.7% of patients, 18.0% of controls) and the presence of TTH in patients with schizophrenia was found statistically significant. Migraine type headache was detected in 2.0% of patients and 11.2% of controls. The ratio of headache was lesser in patients than in the controls. Conclusion: Schizophrenic patients have headache as much as the healthy subjects but they complain less about their headache than the controls do. Further studies with larger samples in patients with schizophrenia would present the importance of the issue and improve the quality of life in patients with schizophrenia contributing the analgesi
    corecore